IOA Madrid Innova Ocular, Madrid, Spain.
IOA Madrid Innova Ocular, Madrid, Spain.
J Cataract Refract Surg. 2019 Feb;45(2):135-145. doi: 10.1016/j.jcrs.2018.09.025. Epub 2018 Nov 30.
To evaluate visual outcomes and satisfaction after implantation of 2 trifocal intraocular lenses (IOLs): a spherical IOL and a toric IOL.
IOA Madrid Innova Ocular, Madrid, Spain.
Prospective, controlled clinical trial.
Patients (>50 years) were implanted bilaterally with either a trifocal spherical hydrophilic IOL (FineVision POD F) if corneal astigmatism was 1.0 diopter (D) or less, or with a trifocal toric hydrophilic IOL (FineVision POD FT) if astigmatism was more than 1.0 D. Outcomes analyzed 3 months after surgery included monocular and binocular visual acuities at distance, near, and intermediate, both uncorrected and corrected. Defocus curves, contrast sensitivity, and patient satisfaction were also assessed.
There was no statistically significant difference between groups in monocular uncorrected distance (UDVA) (P = .38), monocular corrected distance (CDVA) (P = .22), or distance-corrected intermediate (DCIVA) (P = .95) visual acuities; however, the distance-corrected near visual acuity (DCNVA) was slightly better in the spherical IOL group (P = .008). The UDVA was 20/25 or better in 89% of eyes in the spherical IOL group and 93% in the toric IOL group. The DCIVA was 20/32 or better in 92% of eyes in the spherical IOL group and 93% in the toric IOL group at 80 cm (Radner Vissum chart), and 20/32 or better in 100% of eyes in both groups at 63 cm (Colenbrander chart). The DCNVA (Radner chart) was 20/32 or better in 89% of eyes in the spherical IOL group and 90% of eyes in the toric IOL group. There was no difference between the groups in contrast sensitivity, defocus curves, cylinder, or satisfaction results.
Patients had significant improvement in visual acuity and gained functional uncorrected visual acuity across all distances in both groups. Satisfaction was high with both IOLs.
评估植入 2 种三焦点人工晶状体(IOL)后的视力结果和满意度:一种是球面 IOL,另一种是散光矫正型 IOL。
马德里 IOA Innova 眼科,西班牙马德里。
前瞻性、对照临床试验。
如果角膜散光<1.0 屈光度(D),患者(>50 岁)双眼分别植入三焦点球面亲水 IOL(FineVision POD F);如果散光>1.0 D,则植入三焦点散光矫正型亲水 IOL(FineVision POD FT)。术后 3 个月分析的结果包括单眼和双眼的远、近和中距离的未矫正和矫正视力。还评估了离焦曲线、对比敏感度和患者满意度。
两组之间在单眼未矫正远视力(UDVA)(P=0.38)、单眼矫正远视力(CDVA)(P=0.22)或远距矫正中间视力(DCIVA)(P=0.95)方面无统计学差异;然而,球面 IOL 组的远距矫正近视力(DCNVA)略好(P=0.008)。球面 IOL 组 89%的眼 UDVA 达到 20/25 或更好,散光矫正型 IOL 组为 93%。在 80cm(Radner Vissum 图表)处,球面 IOL 组 92%的眼 DCIVA 达到 20/32 或更好,散光矫正型 IOL 组为 93%,两组 100%的眼在 63cm(Colenbrander 图表)处达到 20/32 或更好。球面 IOL 组 89%的眼 DCNVA(Radner 图表)达到 20/32 或更好,散光矫正型 IOL 组为 90%。两组之间的对比敏感度、离焦曲线、柱镜和满意度结果无差异。
两组患者的视力均显著提高,在所有距离均获得了功能性的未矫正视力。两种 IOL 的满意度都很高。